Self-Assembly System Based on Cyclodextrin for Targeted Delivery of Cannabidiol

Area of Science:

• Pharmacology
• Materials Science
• Nanotechnology

Background:

• Cannabidiol (CBD), a cannabinoid from Cannabis sativa L., exhibits diverse pharmacological effects.
• Poor water solubility and specificity hinder pharmaceutical applications of CBD.
• Targeted drug delivery systems are crucial for enhancing therapeutic efficacy and reducing side effects.

Purpose of the Study:

• To develop a novel targeted carrier for cannabidiol (CBD).
• To improve the anticancer activity and specificity of CBD.
• To create a functionalized supramolecular complex for potential clinical application.

Main Methods:

• Synthesis of biotin-grafted ethylenediamine-β-Cyclodextrin (BIO-CD) as a targeted carrier.
• Preparation of amantadine-conjugated CBD (AD-CBD) and its self-assembly with BIO-CD.
• Characterization of inclusion complex formation using various analytical techniques (e.g., MTT assay, CLSM).

Main Results:

• A 1:1 host-guest inclusion complex of AD-CBD and BIO-CD was successfully formed.
• The AD-CBD/BIO-CD complex demonstrated enhanced targeting and anticancer activity against human cancer cell lines compared to free CBD.
• The inclusion complex exhibited pH-sensitive drug release under weakly acidic conditions.

Conclusions:

• The developed AD-CBD/BIO-CD inclusion complex shows significant potential as a targeted anticancer therapeutic.
• This supramolecular approach effectively addresses CBD's limitations in solubility and specificity.
• Further clinical investigations are warranted to explore its therapeutic applicability.